Exagen Inc. entered into the Third Amendment to Loan and Security Agreement with Innovatus Life Sciences Lending I, LP and the other lenders party thereto which amended the term loan agreement, dated as of September 7, 2017, by and among the Company, Innovatus, and other lenders party thereto, as amended on each of November 19, 2019 and October 21, 2021 and, as amended, the . Pursuant to the Third Loan Amendment, the Company prepaid $10.0 million of principal and amended the Original Loan Agreement by, among other things: waiving the Prepayment Fee (as defined in the Loan Agreement) with respect to the Prepayment; (ii) revising the interest rate to the sum of (a) the greater of The Wall Street Journal prime rate or 8.0%, plus (b) 2.0%, of which 1.5% will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026; (iii) extending the interest-only period through March 2026 and the maturity date to December 31, 2026; (iv) decreasing the specified levels of revenue, as measured on the last day of each quarter on a rolling twelve-month basis, that the Company must achieve to satisfy the related financial covenants in the Original Loan Agreement; (v) removing the obligation to comply with the Revenue Covenant during any fiscal quarter, if the Company maintains a minimum aggregate cash balance equal to 50% of the aggregate principal amount of the loan at all times during such quarter; (vi) providing the Company with a cure period in the event it breaches certain covenants; and (vii) revising the definition of “Permitted Indebtedness” to permit the Company to broaden the limits on the Company's ability to incur capitalized lease obligations, finance lease obligations, purchase money indebtedness or equipment financings without Innovatus's prior written consent.